|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OBSL1 |
Gene summary for OBSL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OBSL1 | Gene ID | 23363 |
| Gene name | obscurin like cytoskeletal adaptor 1 | |
| Gene Alias | OBSL1 | |
| Cytomap | 2q35 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O75147 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23363 | OBSL1 | LZE8T | Human | Esophagus | ESCC | 9.25e-05 | 4.48e-02 | 0.067 |
| 23363 | OBSL1 | P2T-E | Human | Esophagus | ESCC | 2.55e-15 | 1.74e-01 | 0.1177 |
| 23363 | OBSL1 | P4T-E | Human | Esophagus | ESCC | 2.02e-06 | 8.24e-02 | 0.1323 |
| 23363 | OBSL1 | P5T-E | Human | Esophagus | ESCC | 3.55e-09 | 5.74e-02 | 0.1327 |
| 23363 | OBSL1 | P8T-E | Human | Esophagus | ESCC | 1.10e-17 | 2.64e-01 | 0.0889 |
| 23363 | OBSL1 | P9T-E | Human | Esophagus | ESCC | 2.73e-12 | 1.63e-01 | 0.1131 |
| 23363 | OBSL1 | P10T-E | Human | Esophagus | ESCC | 5.78e-26 | 9.04e-02 | 0.116 |
| 23363 | OBSL1 | P11T-E | Human | Esophagus | ESCC | 9.15e-03 | 2.82e-01 | 0.1426 |
| 23363 | OBSL1 | P12T-E | Human | Esophagus | ESCC | 1.15e-20 | 1.42e-01 | 0.1122 |
| 23363 | OBSL1 | P15T-E | Human | Esophagus | ESCC | 9.69e-16 | 1.08e-01 | 0.1149 |
| 23363 | OBSL1 | P16T-E | Human | Esophagus | ESCC | 1.06e-15 | 2.18e-01 | 0.1153 |
| 23363 | OBSL1 | P17T-E | Human | Esophagus | ESCC | 4.24e-02 | 7.30e-02 | 0.1278 |
| 23363 | OBSL1 | P20T-E | Human | Esophagus | ESCC | 6.30e-09 | 1.52e-01 | 0.1124 |
| 23363 | OBSL1 | P21T-E | Human | Esophagus | ESCC | 1.71e-20 | 2.23e-01 | 0.1617 |
| 23363 | OBSL1 | P22T-E | Human | Esophagus | ESCC | 5.94e-22 | 1.08e-01 | 0.1236 |
| 23363 | OBSL1 | P23T-E | Human | Esophagus | ESCC | 9.25e-03 | -6.90e-02 | 0.108 |
| 23363 | OBSL1 | P24T-E | Human | Esophagus | ESCC | 1.23e-13 | 1.59e-02 | 0.1287 |
| 23363 | OBSL1 | P26T-E | Human | Esophagus | ESCC | 8.48e-15 | 6.04e-02 | 0.1276 |
| 23363 | OBSL1 | P27T-E | Human | Esophagus | ESCC | 4.27e-13 | 8.10e-02 | 0.1055 |
| 23363 | OBSL1 | P28T-E | Human | Esophagus | ESCC | 1.30e-09 | 8.27e-02 | 0.1149 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:00070883 | Esophagus | ESCC | regulation of mitotic nuclear division | 78/8552 | 110/18723 | 6.96e-08 | 1.21e-06 | 78 |
| GO:00070308 | Esophagus | ESCC | Golgi organization | 101/8552 | 157/18723 | 1.78e-06 | 2.10e-05 | 101 |
| GO:00517831 | Esophagus | ESCC | regulation of nuclear division | 90/8552 | 139/18723 | 4.30e-06 | 4.60e-05 | 90 |
| GO:002260420 | Esophagus | ESCC | regulation of cell morphogenesis | 180/8552 | 309/18723 | 5.19e-06 | 5.45e-05 | 180 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:001072010 | Esophagus | ESCC | positive regulation of cell development | 172/8552 | 298/18723 | 1.74e-05 | 1.55e-04 | 172 |
| GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
| GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
| GO:00340676 | Esophagus | ESCC | protein localization to Golgi apparatus | 23/8552 | 29/18723 | 2.25e-04 | 1.40e-03 | 23 |
| GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| GO:001076920 | Esophagus | ESCC | regulation of cell morphogenesis involved in differentiation | 61/8552 | 96/18723 | 3.12e-04 | 1.85e-03 | 61 |
| GO:00519606 | Esophagus | ESCC | regulation of nervous system development | 237/8552 | 443/18723 | 5.02e-04 | 2.78e-03 | 237 |
| GO:001077018 | Esophagus | ESCC | positive regulation of cell morphogenesis involved in differentiation | 51/8552 | 79/18723 | 5.48e-04 | 3.00e-03 | 51 |
| GO:00519625 | Esophagus | ESCC | positive regulation of nervous system development | 149/8552 | 272/18723 | 1.50e-03 | 7.06e-03 | 149 |
| GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OBSL1 | SNV | Missense_Mutation | c.2265G>T | p.Lys755Asn | p.K755N | O75147 | protein_coding | tolerated(0.28) | benign(0.142) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| OBSL1 | SNV | Missense_Mutation | novel | c.1249N>G | p.Arg417Gly | p.R417G | O75147 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| OBSL1 | SNV | Missense_Mutation | rs768834976 | c.2161N>A | p.Gln721Lys | p.Q721K | O75147 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| OBSL1 | SNV | Missense_Mutation | c.2407N>A | p.Asp803Asn | p.D803N | O75147 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| OBSL1 | SNV | Missense_Mutation | rs757910265 | c.3254N>A | p.Ala1085Glu | p.A1085E | O75147 | protein_coding | tolerated(0.99) | possibly_damaging(0.741) | TCGA-AC-A2QJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| OBSL1 | SNV | Missense_Mutation | rs757910265 | c.3254N>A | p.Ala1085Glu | p.A1085E | O75147 | protein_coding | tolerated(0.99) | possibly_damaging(0.741) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| OBSL1 | SNV | Missense_Mutation | rs765704645 | c.4766C>T | p.Ser1589Leu | p.S1589L | O75147 | protein_coding | tolerated(0.05) | benign(0.021) | TCGA-AC-A6IV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OBSL1 | SNV | Missense_Mutation | c.4189N>A | p.Ala1397Thr | p.A1397T | O75147 | protein_coding | tolerated(0.51) | benign(0.01) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| OBSL1 | SNV | Missense_Mutation | novel | c.2329G>C | p.Glu777Gln | p.E777Q | O75147 | protein_coding | tolerated(0.11) | benign(0.328) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| OBSL1 | SNV | Missense_Mutation | rs757910265 | c.3254N>A | p.Ala1085Glu | p.A1085E | O75147 | protein_coding | tolerated(0.99) | possibly_damaging(0.741) | TCGA-BH-A5J0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |